crisaborole vs Roflumilast (Zoryve)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: PDE4 · full Atopic Dermatitis pipeline
crisaborole · Eucrisa
Marketed by Pfizer
NCT02118792 · Phase 3 · completed
This was a randomized, quadruple-blind, vehicle-controlled trial with 763 participants. Its clinical primary efficacy endpoint—clear or almost clear skin with at least a two-grade improvement at Day 29—was met, with 31.4% success on crisaborole versus 18.0% on vehicle (p<0.001).
Next expected readout: January 2027 · NCT07162896 (registry estimate)
Reported efficacy
Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global Assessment (ISGA) at Day 29; Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs) (AEs: Baseline (Day 1) up to Day 29, SAEs: Baseline (Day 1) up to Day 36); Number of Participants With Clinically Significant Change From Baseline in Vital Signs at Day 29 (Baseline, Day 29); Number of Participants With Clinically Significant Change From Baseline in Laboratory Values at Day 29 (Baseline, Day 29): Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global Assessment (ISGA) at Day 29 (Day 29): AN2728 Topical Ointment, 2 Percent 32.8% vs AN2728 Topical Ointment, Vehicle 25.4% (met)
Result source: NCT02118766
Roflumilast (Zoryve)
Marketed by Arcutis Biotherapeutics and partners
NCT06631170 · Phase 3 · completed
The trial was randomized, fully blinded, and vehicle-controlled with a validated disease-severity measure as its primary endpoint, and roflumilast cream produced significantly more treatment successes than vehicle (31.9% vs 6.7%, P<0.0001).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: August 2027 · NCT07560618 (registry estimate)
Reported efficacy
Percentage of subjects with vIGA-AD success (Baseline, week 4): Primary endpoint, Week 4 IGA (vIGA-AD) treatment-success rate: 31.9% with 0.15% roflumilast cream vs 6.7% with vehicle (P<0.0001) (met)
Result source: NCT06631170
Results for Atopic Dermatitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | crisaborole | Roflumilast (Zoryve) |
|---|---|---|
| EASI-75 | 46.4% vs 27.6%+18.8 vs placeboNCT043601873 other results
| 43.2% vs 22%+21.2 vs placeboNCT047735878 other results
|
| IGA 0/1 with 2-point improvement | —Trial running · NCT07162896 | —Not posted · NCT06631170 |
| EASI-90 | —Trial running · NCT07162896 | 17.4% vs 17.8%−0.4 vs placeboNCT039160815 other results
|
| EASI, % change | -59.9% vs -42.8%−17.1 vs placeboNCT0436018741 other results
| -69.4% vs -55.8%−13.5 vs placeboNCT039160815 other results
|
EASI-75
- crisaborole
- 46.4% vs 27.6%+18.8 vs placeboNCT04360187
3 other results
- 38.2% vs 26.3% NCT04360187
- 26.3% vs 15.4% NCT04360187
- 11.2% vs 6.1% NCT04360187
- Roflumilast (Zoryve)
- 43.2% vs 22%+21.2 vs placeboNCT04773587
8 other results
- 42% vs 19.7% NCT04773600
- 39.4% vs 20.6% NCT04845620
- 56.5% vs 31.1% NCT03916081
- 51.1% vs 31.1% NCT03916081
- 17.4% vs 24.4% NCT03916081
- 31.1% vs 24.4% NCT03916081
- 8.7% vs 2.2% NCT03916081
- 13.3% vs 2.2% NCT03916081
IGA 0/1 with 2-point improvement
- crisaborole
- —Trial running · NCT07162896
- Roflumilast (Zoryve)
- —Not posted · NCT06631170
EASI-90
- crisaborole
- —Trial running · NCT07162896
- Roflumilast (Zoryve)
- 17.4% vs 17.8%−0.4 vs placeboNCT03916081
5 other results
- 26.7% vs 17.8% NCT03916081
- 2.2% vs 8.9% NCT03916081
- 13.3% vs 8.9% NCT03916081
- 0% vs 0% NCT03916081
- 2.2% vs 0% NCT03916081
EASI, % change
- crisaborole
- -59.9% vs -42.8%−17.1 vs placeboNCT04360187
41 other results
- -10.2% vs 2.9% NCT04040192
- 407.5% vs 2.9% NCT04040192
- -10.3% vs -0.5% NCT04040192
- -59.9% vs -42.8% NCT04360187
- -55.0% vs -42.9% NCT04360187
- -49.6% vs -37.1% NCT04360187
- -36.6% vs -21.4% NCT04360187
- 34.3% vs 1.0% NCT04040192
- 239.9% vs 1.0% NCT04040192
- 10.4% vs -21.3% NCT04040192
- -8.2% vs -0.1% NCT04040192
- 401.4% vs -0.1% NCT04040192
- -9.4% vs 2.2% NCT04040192
- 28.0% vs 26.3% NCT04040192
- 272.9% vs 26.3% NCT04040192
- -0.5% vs -14.8% NCT04040192
- -45.4% vs 26.4% NCT04040192
- 264.7% vs 26.4% NCT04040192
- -74.3% vs 200% NCT04040192
- 6.9% vs -20.6% NCT04040192
- 270.2% vs -20.6% NCT04040192
- -10.8% vs -35.6% NCT04040192
- -33.0% vs 19.2% NCT04040192
- 454.0% vs 19.2% NCT04040192
- -34.5% vs 0% NCT04040192
- -19.3% vs 13.6% NCT04040192
- 341.2% vs 13.6% NCT04040192
- -27.8% vs -28.4% NCT04040192
- 211.1% vs -56.0% NCT04040192
- 184.3% vs -56.0% NCT04040192
- -12.9% vs 10% NCT04040192
- 330.8% vs 10% NCT04040192
- -47.6% vs 2.2% NCT04040192
- 127.6% vs -59.7% NCT04040192
- 444% vs -59.7% NCT04040192
- -30.0% vs -22.2% NCT04040192
- 390.3% vs -22.2% NCT04040192
- -39.1% vs -27.3% NCT04040192
- -49.8% vs -39.3% NCT04040192
- 250.1% vs -39.3% NCT04040192
- -59.9% vs -54.3% NCT04040192
- Roflumilast (Zoryve)
- -69.4% vs -55.8%−13.5 vs placeboNCT03916081
5 other results
- -72.3% vs -55.8% NCT03916081
- -54.3% vs -48.5% NCT03916081
- -57.6% vs -48.5% NCT03916081
- -35.8% vs -24.4% NCT03916081
- -34.7% vs -24.4% NCT03916081
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. crisaborole: 7 of 7 rows · Roflumilast (Zoryve): 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | crisaborole Rows use multiple source trials | Roflumilast (Zoryve) Rows use multiple source trials |
|---|---|---|
| BSA absolute change · percentage points | 6.25% (n=175) vs 1.16% (n=129) placebo @ 4wk2% BIDa,b,c,d NCT04040192 · Phase 3 · registry result, not featured evidence show 3 more doses0.52% (n=125) vs 1.16% (n=129) placebo @ 4wk2% QD NCT04040192 · Phase 3 · registry result, not featured evidence 0.53% (n=125) vs 1.2% (n=129) placebo @ 4wk2% QD NCT04040192 · Phase 3 · registry result, not featured evidence 4.17% (n=81) vs 6.92% (n=96) placebo @ 4wk2% QD NCT04040192 · Phase 3 · registry result, not featured evidence | -4.41% (n=46) vs -4.16% (n=45) placebo @ 4wk0.05%a,b,c,d NCT03916081 · Phase 2 · registry result, not featured evidence show 1 more dose-5.1% (n=45) vs -4.16% (n=45) placebo @ 4wk0.15% NCT03916081 · Phase 2 · registry result, not featured evidence |
| EASI-50 responder rate · % of participants | 72.7% (n=260) vs 49.4% (n=131) placebo @ 4.14wk2% twice a dayb,c,d,e NCT04360187 · Phase 3 · registry result, not featured evidence | 69.6% (n=46) vs 55.6% (n=45) placebo @ 4wk*0.05%a,b,c,d,e NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 32 Participants as posted show 1 more dose73.3% (n=45) vs 55.6% (n=45) placebo @ 4wk*0.15% NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 33 Participants as posted |
| SCORAD absolute change · score | 25.78 vs 17.2 placebo score @ 12.8571wkf,c,d,g NCT03832010 · Phase 4 · registry result, not featured evidence | -2.3 vs -1.75 placebo score @ 2.142857wk0.5%f,c,d,g NCT01856764 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 6%2% ointmenth NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3 show 22 more results—2% ointment NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3 5.9%2% NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3 —2% NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3 50% NCT03832010 · Phase 4 · registry result, not featured evidence 3.6%2% NCT03356977 · Phase 4 · registry result, not featured evidence —2% QD NCT04040192 · Phase 3 · registry result, not featured evidence —2% QD NCT04040192 · Phase 3 · registry result, not featured evidence —2% QD NCT04040192 · Phase 3 · registry result, not featured evidence —2% BID NCT04040192 · Phase 3 · registry result, not featured evidence 5.8%2% twice a day NCT04360187 · Phase 3 · registry result, not featured evidence 0%2% QD NCT03954158 · Phase 2 · registry result, not featured evidence · combination 0%2% BID NCT03954158 · Phase 2 · registry result, not featured evidence · combination 0%2% BID NCT03954158 · Phase 2 · registry result, not featured evidence · combination 0%2% QD NCT03954158 · Phase 2 · registry result, not featured evidence · combination — NCT03233529 · Phase 2 · registry result, not featured evidence 0%0.5% + 2% once daily NCT01602341 · Phase 2 · registry result, not featured evidence · combination 2.4%0.5% + 2% twice daily NCT01602341 · Phase 2 · registry result, not featured evidence · combination 12%2% NCT01301508 · Phase 2 · registry result, not featured evidence · combination 4.8%1% NCT01301508 · Phase 2 · registry result, not featured evidence · combination 4.3%2 percent NCT01652885 · Phase 1/2 · registry result, not featured evidence 0%Cohort 1: Crisaborole Ointment 2% NCT03260595 · Phase 1 · registry result, not featured evidence 0%Cohort 2: Crisaborole Ointment 2% NCT03260595 · Phase 1 · registry result, not featured evidence | 6.7%0.15% creami NCT04773587 · Phase 3 show 7 more results9.1%0.15% cream NCT04773600 · Phase 3 6.2%0.05% cream NCT04845620 · Phase 3 34.2%0.15% NCT04804605 · Phase 3 · registry result, not featured evidence 33.8%0.15% NCT04804605 · Phase 3 · registry result, not featured evidence 8.7%0.05% NCT03916081 · Phase 2 · registry result, not featured evidence 2.2%0.15% NCT03916081 · Phase 2 · registry result, not featured evidence 0%0.5% NCT01856764 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 1%2% ointmenth NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3 show 22 more results—2% ointment NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3 1.4%2% NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3 —2% NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3 — NCT03832010 · Phase 4 · registry result, not featured evidence —2% NCT03356977 · Phase 4 · registry result, not featured evidence —2% QD NCT04040192 · Phase 3 · registry result, not featured evidence —2% QD NCT04040192 · Phase 3 · registry result, not featured evidence —2% QD NCT04040192 · Phase 3 · registry result, not featured evidence —2% BID NCT04040192 · Phase 3 · registry result, not featured evidence 4.2%2% twice a day NCT04360187 · Phase 3 · registry result, not featured evidence —2% QD NCT03954158 · Phase 2 · registry result, not featured evidence · combination —2% BID NCT03954158 · Phase 2 · registry result, not featured evidence · combination —2% BID NCT03954158 · Phase 2 · registry result, not featured evidence · combination —2% QD NCT03954158 · Phase 2 · registry result, not featured evidence · combination — NCT03233529 · Phase 2 · registry result, not featured evidence 0%0.5% + 2% once daily NCT01602341 · Phase 2 · registry result, not featured evidence · combination 2.4%0.5% + 2% twice daily NCT01602341 · Phase 2 · registry result, not featured evidence · combination —2% NCT01301508 · Phase 2 · registry result, not featured evidence · combination —1% NCT01301508 · Phase 2 · registry result, not featured evidence · combination 4.3%2 percent NCT01652885 · Phase 1/2 · registry result, not featured evidence —Cohort 1: Crisaborole Ointment 2% NCT03260595 · Phase 1 · registry result, not featured evidence —Cohort 2: Crisaborole Ointment 2% NCT03260595 · Phase 1 · registry result, not featured evidence | 1.4%0.15% creami NCT04773587 · Phase 3 show 7 more results1.8%0.15% cream NCT04773600 · Phase 3 1.1%0.05% cream NCT04845620 · Phase 3 2.3%0.15% NCT04804605 · Phase 3 · registry result, not featured evidence 4.6%0.15% NCT04804605 · Phase 3 · registry result, not featured evidence 2.2%0.05% NCT03916081 · Phase 2 · registry result, not featured evidence 0%0.15% NCT03916081 · Phase 2 · registry result, not featured evidence —0.5% NCT01856764 · Phase 2 · registry result, not featured evidence |
| Serious AEs | —2% ointmenth NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3 show 22 more results0.6%2% ointment NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3 —2% NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3 1%2% NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3 0% NCT03832010 · Phase 4 · registry result, not featured evidence 0.7%2% NCT03356977 · Phase 4 · registry result, not featured evidence —2% QD NCT04040192 · Phase 3 · registry result, not featured evidence 1.3%2% QD NCT04040192 · Phase 3 · registry result, not featured evidence 1.5%2% QD NCT04040192 · Phase 3 · registry result, not featured evidence 0.6%2% BID NCT04040192 · Phase 3 · registry result, not featured evidence 0.4%2% twice a day NCT04360187 · Phase 3 · registry result, not featured evidence 0%2% QD NCT03954158 · Phase 2 · registry result, not featured evidence · combination 0%2% BID NCT03954158 · Phase 2 · registry result, not featured evidence · combination 0%2% BID NCT03954158 · Phase 2 · registry result, not featured evidence · combination 0%2% QD NCT03954158 · Phase 2 · registry result, not featured evidence · combination 0% NCT03233529 · Phase 2 · registry result, not featured evidence 0%0.5% + 2% once daily NCT01602341 · Phase 2 · registry result, not featured evidence · combination 0%0.5% + 2% twice daily NCT01602341 · Phase 2 · registry result, not featured evidence · combination 0%2% NCT01301508 · Phase 2 · registry result, not featured evidence · combination 0%1% NCT01301508 · Phase 2 · registry result, not featured evidence · combination 0%2 percent NCT01652885 · Phase 1/2 · registry result, not featured evidence 0%Cohort 1: Crisaborole Ointment 2% NCT03260595 · Phase 1 · registry result, not featured evidence 0%Cohort 2: Crisaborole Ointment 2% NCT03260595 · Phase 1 · registry result, not featured evidence | 0.9%0.15% creami NCT04773587 · Phase 3 show 7 more results0.9%0.15% cream NCT04773600 · Phase 3 0.2%0.05% cream NCT04845620 · Phase 3 1.1%0.15% NCT04804605 · Phase 3 · registry result, not featured evidence 1.4%0.15% NCT04804605 · Phase 3 · registry result, not featured evidence 2.2%0.05% NCT03916081 · Phase 2 · registry result, not featured evidence 0%0.15% NCT03916081 · Phase 2 · registry result, not featured evidence 0%0.5% NCT01856764 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 2% ointmenth upper respiratory tract infection 3.1% (placebo 2%) application site pain 2.7% (placebo 1.2%) nasopharyngitis 1.8% (placebo 2.4%) NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3 show 19 more results2% burning/stinging: mild 23.9% (placebo 19%) burning/stinging: moderate 18.1% (placebo 17.1%) burning/stinging: severe 8.2% (placebo 4%) NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3 burning sensation after the first application of the assigned study medication. 12.5% (placebo 0%) NCT03832010 · Phase 4 · registry result, not featured evidence 2% pyrexia 9.5% diarrhoea 7.3% upper respiratory tract infection 7.3% NCT03356977 · Phase 4 · registry result, not featured evidence 2% QD dermatitis atopic 2.6% (placebo 2.2%) application site acne 1.3% (placebo 0%) application site infection 1.3% (placebo 3.4%) NCT04040192 · Phase 3 · registry result, not featured evidence 2% QD covid-19 3.7% (placebo 1.1%) upper respiratory tract infection 3% (placebo 1.1%) headache 2.2% (placebo 1.1%) NCT04040192 · Phase 3 · registry result, not featured evidence 2% BID application site pain 5.6% (placebo 1.1%) dermatitis atopic 2.4% (placebo 2.2%) upper respiratory tract infection 2% (placebo 1.1%) NCT04040192 · Phase 3 · registry result, not featured evidence 2% twice a day application site pain 13.1% (placebo 3.8%) dermatitis atopic 7.7% (placebo 11.5%) application site discolouration 3.5% (placebo 0.8%) NCT04360187 · Phase 3 · registry result, not featured evidence 2% QD application site irritation 15% application site pruritus 15% application site folliculitis 5% NCT03954158 · Phase 2 · registry result, not featured evidence · combination 2% BID application site irritation 19% oropharyngeal pain 14.3% application site pruritus 9.5% NCT03954158 · Phase 2 · registry result, not featured evidence · combination 2% BID application site pain 5% application site pruritus 5% hand-foot-and-mouth disease 5% NCT03954158 · Phase 2 · registry result, not featured evidence · combination 2% QD arthralgia 5% hand-foot-and-mouth disease 5% application site coldness 0% NCT03954158 · Phase 2 · registry result, not featured evidence · combination dermatitis atopic 12.8% nasopharyngitis 12.8% application site pain 10.3% NCT03233529 · Phase 2 · registry result, not featured evidence 0.5% + 2% once daily application site pain 4.5% application site pruritus 2.3% asthma 2.3% NCT01602341 · Phase 2 · registry result, not featured evidence · combination 0.5% + 2% twice daily nasopharyngitis 4.8% application site pruritus 2.4% arthralgia 2.4% NCT01602341 · Phase 2 · registry result, not featured evidence · combination 2% upper respiratory tract infection 24% headache 8% application site erythema 4% NCT01301508 · Phase 2 · registry result, not featured evidence · combination 1% upper respiratory tract infection 14.3% application site cellulitis 4.8% application site erythema 4.8% NCT01301508 · Phase 2 · registry result, not featured evidence · combination 2 percent application site pain 13% nasopharyngitis 13% dysmenorrhoea 5.3% NCT01652885 · Phase 1/2 · registry result, not featured evidence application site coldness 0% (placebo 50%) application site irritation 0% (placebo 50%) application site pain 0% (placebo 50%) NCT03260595 · Phase 1 · registry result, not featured evidence application site irritation 70% (placebo 50%) application site pain 40% (placebo 50%) application site coldness 10% (placebo 50%) NCT03260595 · Phase 1 · registry result, not featured evidence | 0.15%i covid-19 4.1% nasopharyngitis 2.7% upper respiratory tract infection 2.1% NCT04804605 · Phase 3 · registry result, not featured evidence show 2 more results0.15% covid-19 5.5% upper respiratory tract infection 5.5% nasopharyngitis 3.7% NCT04804605 · Phase 3 · registry result, not featured evidence 0.5% nasopharyngitis 15% (placebo 0%) alanine aminotransferase increased 5% (placebo 0%) application site pain 5% (placebo 5%) NCT01856764 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase 2.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 4.14 weeks versus 4 weeks.
- fTrial phases differ: Phase 4 versus Phase 2.
- gAssessment timepoints differ: 12.8571 weeks versus 2.142857 weeks.
- hPopulation comparability has not been reviewed for 19 of these studies.
- iPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
crisaborole
show 6 more results
show 6 more results
show 1 more result
show 1 more result
show 4 more results
show 3 more results
show 4 more results
show 15 more results
+ 30 further endpoints in the CSV export.
Roflumilast (Zoryve)
show 17 more results
show 5 more results
show 2 more results
show 19 more results
show 9 more results
show 9 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
+ 1 further endpoint in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: crisaborole's landscape · Roflumilast (Zoryve)'s landscape